Profile

Cover photo
Advaxis, Inc.
32 followers|18,065 views
AboutPostsPhotosYouTube

Stream

Pinned

Advaxis, Inc.

Shared publicly  - 
 
Our Lm Technology™ utilizes the efficiency of the entire immune system by teaching it to recognize the tumor as a threat, and by weakening the tumor’s defenses. Once educated by Lm Technology™, the immune system—specifically, its killer T cells—are enabled to do their job and work to destroy the cancer. http://www.advaxis.com/lm-technology/
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is scheduled to present key milestones and company initiatives at the 3rd Annual Jefferies Immuno-Oncology Summit on April 8. Read the full announcement here: 
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
We are pleased to announce that Advaxis has elected Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors. Read the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is pleased to announce that our Phase 2 study in head and neck cancer has been selected as a late-breaker poster presentation at the American Association for Cancer Research Annual Meeting. Read the full announcement here: 
1
Add a comment...

Advaxis, Inc. has a new profile photo.

Shared publicly  - 
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
We’re pleased to announce Advaxis will be presenting at the 2016 RBC Capital Markets’ Healthcare Conference. Read the full story here:
1
Add a comment...
Have them in circles
32 people
jim dooley's profile photo
Michael Higgins's profile photo
Phillip Ressler (macressler)'s profile photo
Brad Loncar's profile photo
Giovanna Beeney's profile photo
yolande lorijn's profile photo
Vincent Grillo's profile photo
Eduardo Zawadzki's profile photo
Shon Booker's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is pleased to announce that the combination trial with Merck has completed the first two dose-escalation cohorts, and the study evaluating ADXS-PSA has launched the third cohort. Read the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has announced the completion of the first dose-escalation cohort in their combination trial with MedImmune, and has commenced the second dose-escalation cohort. Read the full announcement here: 
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced today that Gregory Mayes, Executive Vice President and Chief Operating Officer, will present at the 27th annual ROTH Capital Partners Conference. Read the full announcement here: 
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announces CEO Daniel J. O'Connor will present at the Cowen and Company 36th Annual Health Care Conference on March 9. Read the full announcement here: 
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is collaborating with the Farrah Fawcett Foundation to develop drugs for HPV-associated anal cancers. Learn more here:
The biotech company is working with FAWCETT and Brown University to develop new regimens for the socially stigmatized condition.
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has released a letter to shareholders from President and CEO Dan O’Connor. Read the full letter here: http://bit.ly/1TaG3Cv
1
Add a comment...
People
Have them in circles
32 people
jim dooley's profile photo
Michael Higgins's profile photo
Phillip Ressler (macressler)'s profile photo
Brad Loncar's profile photo
Giovanna Beeney's profile photo
yolande lorijn's profile photo
Vincent Grillo's profile photo
Eduardo Zawadzki's profile photo
Shon Booker's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.